This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: ASCO

I'm more than willing to view Delcath's CS data as strong enough for approval since the bear thesis focuses more on the commercial market than efficacy and safety. With that said, two patients treated with the CS procedure died from neutropenic sepsis. Likely, this means some of the ultra-high dose of the chemotherapy melphalan used to kill liver tumors escaped the filters in the CS device and got into the patient's blood stream.

The FDA previously placed Delcath's CS clinical trial on hold due to a safety issue. That hold was lifted and the study was completed, but the disclosure of the two deaths from neutropenic sepsis may concern FDA enough to delay the system's approval until the agency is satisfied that the melphalan filters are doing the job.

Delcath said this week that the FDA approval filing will be completed in October. Assuming a six-month review, the FDA's approval decision date will come next April. Before that, expect an FDA advisory panel to review the CS data.

Next week: Non-ASCO questions! Promise.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CTIC $1.83 0.00%
BMY $63.56 0.00%
CELG $114.57 0.00%
CLDX $26.93 0.00%
DCTH $0.93 0.00%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs